金葡液胸腔内注射治疗癌性胸水的临床研究

A Clinical Study of Intrapleural Therapy with Natural Growth Factor for Malignant Pleural Effusion

[目的]研究金葡液治疗癌性胸水的临床疗效。[方法]45例癌性胸水病人被随机分为3组 ,均行胸腔穿刺术,尽量抽尽胸水。单用金葡液组(单金组) :胸腔内注入金葡液2000U。单用顺铂组(单化组) :胸腔内注入顺铂40mg～60mg。金葡液联合顺铂组(联合组) :胸腔内注入金葡液2000U加顺铂40mg～60mg。每周2次 ,一般2～4次。[结果]单金组、单化组、联合组治疗癌性胸水的有效率(CR +PR)分别为53 3 %、46 7%、86 7% ;单金组与单化组比较无明显差异(P>0 05) ,联合组分别与单金组和单化组比较均差异显著(P<0 05)。在活动状况提高方面 ,单金组稍优于单化组(P>0 05) ,联合组明显优于单化组(P<0 05)。联合组的白细胞下降及恶心呕吐的发生率明显低于单化组(P<0 05)。[结论]金葡液是治疗癌性胸水的有效药物 ,与顺铂联合可增效减毒 ,提高生存质量。

To study the clinical effects on malignant pleural effusion treated by Natural Growth Factor(NGF)Fortyfive cases were devided randomizedly into 3 groupsMalignant pleural effusion was asperated completely for all the cases①NGF alone group(NAG):NGF 2000U intrapleural②chemotherapy alone group(CAG):cisplatin 40mg～60mg intrapleural③NGF and chemotherapycombination group(NCCG):NGF 2000U+cisplatin 40mg～60mg intrapleuralThe treatment were given twice a week,generally for 2～4 cyclesThe response rate (CR+PR) of NAG,CAG,NCCG was 533%,467%,867% respectivelyThe response rate of NAG was higher than that of CAG(P>005)However,the response rate of NCCG was significantly higher than that of NAG,CAG(P<005)For the performance status improvement,NAG showed better than CAG(P>005)NCCG showed significantly better than CAG(P<005)The rate of occurring leucopenia,nausea and vomiting in NCCG were significantly lower than that in CAG(P<005)[Conclusion]NGF is an effective agent for treating malignant pleural effusionNGF combined with cisplatin can reduce the therapeutic side effect and improve patients quality of life